| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2159385 | Radiotherapy and Oncology | 2010 | 4 Pages |
Abstract
Especially for non-small cell lung cancer, FDG-PET has in the majority of the patients led to the safe decrease of radiotherapy volumes, enabling radiation-dose escalation and, experimentally, redistribution of radiation doses within the tumor. In limited-disease small cell lung cancer, the role of FDG-PET is emerging.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Dirk De Ruysscher, Carl-Martin Kirsch,